Publication - 21 Mar, 2024
PNAS
Our Purpose
Our core platform technology pertains to proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody, and are designed to deliver payloads, including mRNA or gene editing tools, capable of reprograming specific cell types in vivo.
Our Science
Repeat dosing and drug-like pharmacokinetics
Tunability to fit safety and efficacy bars depending on disease indication
Scalable manufacturing
Potential administration in earlier disease stages and in outpatient settings
Cell type-specific targeting of disease-relevant cells
Modular therapeutic product design with a toolbox of tLNP constructs and a broad range of payloads
Our Approach
We can deliver mRNA-encoded CARs to specific subsets of immune cells, engineering them to eliminate pathogenic cells that express antigens recognized by the CAR.
By delivering mRNA-encoded gene editing machinery to pathogenic cells, we can modify the cells’ DNA to treat genetic disease.
Presentations and Publications
Publication - 21 Mar, 2024
PNAS
Publication - 27 Jul, 2023
Science
Publication - 29 Aug, 2022
Cell & Gene Therapy Insights
Publication - 21 Apr, 2022
The New England Journal of Medicine
Publication - 28 Feb, 2022
Nature Metabolism
Publication - 6 Jan, 2022
Science
Publication - 6 Jan, 2022
FierceBiotech
Publication - 6 Jan, 2022
NewScientist
Publication - 3 Jun, 2021
Cell Press
Publication - 19 Dec, 2019
The New England Journal of Medicine
Publication - 11 Sep, 2019
Nature
Press Release - 26 Sep, 2024
Press Release - 25 Sep, 2024
Press Release - 27 Aug, 2024
Press Release - 31 May, 2024
Press Release - 20 Mar, 2024
Press Release - 1 Mar, 2024
Press Release - 8 Jan, 2024
Press Release - 31 Oct, 2023
Press Release - 2 Oct, 2023
Press Release - 26 Sep, 2023
Press Release - 23 Mar, 2023
Press Release - 22 Mar, 2023
Press Release - 22 Feb, 2023
Press Release - 24 Jan, 2023
Press Release - 12 Oct, 2022
Press Release - 14 Sep, 2022
Presentation - 4 Nov, 2023
Presentation - 3 Nov, 2023
News Coverage - 26 Sep, 2024
Endpoints
News Coverage - 16 Sep, 2024
Nature Reviews Drug Discovery
News Coverage - 15 Jul, 2024
PharmaVoice
News Coverage - 12 Apr, 2024
MIT Technology Review
News Coverage - 20 Mar, 2024
San Diego Union Tribune
News Coverage - 16 Feb, 2024
BioCentury
News Coverage - 16 Nov, 2023
Forbes
News Coverage - 7 Nov, 2023
Endpoints
News Coverage - 3 Nov, 2023
Biotech TV
News Coverage - 18 Oct, 2022
BioPharma Dive
News Coverage - 14 Sep, 2022
Endpoints
News Coverage - 14 Sep, 2022
STAT
Careers
We are seeking people who share our passion and purpose of pushing the boundaries of medicine by enabling targeted in vivo engineering of cells.
Creativity
Pioneering new medicines requires all of us to harness our best and boldest thinking. We are intellectually curious, not afraid to take risks and are open to continuous learning. Our creativity is anchored in integrity, scientific rigor, and the pursuit of quality solutions for patients.
Collaboration
The complexity of our work requires us to trust each other and work together at every level. We communicate clearly, seek diverse perspectives, and truly listen, all while holding each other accountable to do our best work to move this science forward.
Commitment
This work is hard—there will be setbacks that we need to learn from. We bring our passion for patients to everything we do; we are resilient and resolved because we know the impact of our work can make a difference for patients, everywhere.
An Ongoing Commitment to DEI
An element of Capstan’s mission is to create medicines that enable broader access for patients. We can only achieve that by building a company that represents and values the different voices and perspectives that is reflective of our world today. We will continue to build an inclusive culture that supports our employees in bringing their best selves to work and enables them to pursue opportunities in a fair and equitable way.
Want to be a Capstaneer?
We don’t currently have any openings. For job opportunities, please inquire at [email protected].
Contact
9880 Campus Point Dr
Suite 220